PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

GHENT, Belgium, July 29, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Taube Hodson Stonex Partners LLP.

Taube Hodson Stonex Partners LLP notified Ablynx that they have dropped below the 5% threshold and now hold 2,410,681 Ablynx shares, which represent 4.42% of the current 54,487,457 outstanding Ablynx shares.

Full versions of all transparency notifications are available on Ablynx website, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Merck Serono, Novartis and Taisho Pharmaceutical. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

Voor bijkomende informatie, gelieve contact op te nemen met

Ablynx:

Dr Edwin Moses Gedelegeerd Bestuurder t:   +32 (0)9 262 00 07 m: +32 (0)473 39 50 68 e:  [email protected]

Marieke Vermeersch Associate Director Investor Relations t:   +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e:  [email protected] Volg ons op Twitter @AblynxABLX

Ablynx media relaties Instinctif Partners:

Sue Charles, Daniel Gooch London office t:  +44 (0)20 7866 7905 e:  [email protected]

Jim Rusagara Brussels office t:  +32 (0)2 626 9500 e:  [email protected]

pdf format of the press release http://hugin.info/137912/R/1941813/702049.pdf

HUG#1941813

You May Also Be Interested In

• Valstybės investicinis kapitalas UAB audited Annual information for the year 2023
• Akanda Appoints Cooper to the Board of Directors
• Robbins LLP Reminds LYFT Stockholders of Pending May 6, 2024 Lead Plaintiff Deadline